We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

138 hedge funds and large institutions have $1.18B invested in Acceleron Pharma in 2016 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 45 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $1.02B → $1.18B (+$162M)

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

1% more funds holding

Funds holding: 136 → 138 (+2)

2% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 45

18% less call options, than puts

Call options by funds: $2.19M | Put options by funds: $2.68M

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
138
Holders Change
+2
Holders Change %
+1.47%
% of All Funds
3.68%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
17
Increased
46
Reduced
45
Closed
15
Calls
$2.19M
Puts
$2.68M
Net Calls
-$490K
Net Calls Change
+$2.92M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$25.3M
2
LCM
Laurion Capital Management
New York
+$22.9M
3
Goldman Sachs
Goldman Sachs
New York
+$13.9M
4
RCM
RA Capital Management
Massachusetts
+$10.6M
5
HIM
Hillhouse Investment Management
Cayman Islands
+$9.94M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$12.6M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
-$8.52M
3
CS
Credit Suisse
Switzerland
-$6.06M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.91M
5
ORI
Oak Ridge Investments
Illinois
-$3.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
IHM
51
Iguana Healthcare Management
New York
$2.53M +$663K +20,000 +40%
TD Asset Management
52
TD Asset Management
Ontario, Canada
$2.35M +$99.4K +3,000 +5%
California State Teachers Retirement System (CalSTRS)
53
California State Teachers Retirement System (CalSTRS)
California
$2.1M +$19.9K +600 +1%
Renaissance Technologies
54
Renaissance Technologies
New York
$2.08M +$1.91M +57,600 New
PP
55
PDT Partners
New York
$1.89M – – –
AA
56
ALPS Advisors
Colorado
$1.74M -$144K -4,357 -8%
Invesco
57
Invesco
Georgia
$1.67M +$1.53M +46,216 New
MOACM
58
Mutual of America Capital Management
New York
$1.62M – – –
Bank of America
59
Bank of America
North Carolina
$1.6M -$72K -2,174 -5%
TA
60
Teachers Advisors
New York
$1.59M – – –
Swiss National Bank
61
Swiss National Bank
Switzerland
$1.57M -$49.7K -1,500 -3%
AllianceBernstein
62
AllianceBernstein
Tennessee
$1.56M – – –
TC
63
TFS Capital
Pennsylvania
$1.52M -$504K -15,204 -27%
CCP
64
Clough Capital Partners
Massachusetts
$1.44M -$109K -3,300 -8%
UBS Group
65
UBS Group
Switzerland
$1.32M -$181K -5,464 -13%
BlackRock
66
BlackRock
New York
$1.27M -$17.9K -541 -2%
HLA
67
Hamilton Lane Advisors
Pennsylvania
$1.21M – – –
American Century Companies
68
American Century Companies
Missouri
$1.19M -$2.68K -81 -0.2%
EWM
69
Evercore Wealth Management
New York
$1.19M – – –
First Trust Advisors
70
First Trust Advisors
Illinois
$1.14M +$1.04M +31,533 New
New York State Common Retirement Fund
71
New York State Common Retirement Fund
New York
$1.11M +$215K +6,500 +27%
BBA
72
Baker Bros. Advisors
New York
$1.04M – – –
RhumbLine Advisers
73
RhumbLine Advisers
Massachusetts
$996K +$16.6K +500 +2%
ProShare Advisors
74
ProShare Advisors
Maryland
$974K -$137K -4,146 -13%
CCM
75
Cupps Capital Management
Illinois
$966K -$548K -16,548 -38%
1 2
3
4 5

XLRN Hedge Fund Activity: Q3 2016 in Review

138 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2016, worth a combined $1.18B — up 16% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new XLRN positions and 15 closed out — a net gain of 2 holders — while 46 added to existing stakes and 45 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $25.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $12.6M sold.

  • 138 institutional investors held Acceleron Pharma (XLRN) as of Q3 2016, up from 136 in Q2 2016.
  • Funds reported $1.18B of Acceleron Pharma stock for Q3 2016, up 16% quarter-over-quarter.
  • 17 funds opened new Acceleron Pharma positions in Q3 2016 and 15 closed out, a net change of +2 holders.
  • The largest Acceleron Pharma buyer in Q3 2016 was Morgan Stanley, an estimated $25.3M added.
  • The largest Acceleron Pharma seller in Q3 2016 was EcoR1 Capital, an estimated $12.6M sold.

Based on aggregated 13F filings for Q3 2016.